ArticleParasitology research2026
Association between Toxoplasma gondii seropositivity and Alzheimer's disease: a case-control study.
Article in Parasitology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative condition marked by declining cognitive function and memory deterioration. Emerging evidence suggests that infectious agents, including Toxoplasma gondii, may contribute to the risk of developing this disorder. Because previous studies on this association have produced limited and inconsistent results, we examined the link between T. gondii infection and Alzheimer's disease. This case-control study included 90 recently diagnosed AD patients from Ayatollah Rouhani Hospital and Clinic in Babol, Iran, and 91 healthy individuals as controls. After obtaining written informed consent, serum samples were collected from both groups. AD was determined through expert clinical evaluation, and the Mini-Mental State Examination (MMSE) was used to assess cognitive status and disease severity. Anti-T. gondii IgG antibodies were detected using ELISA. Data were analyzed in SPSS using chi-square tests, and odds ratios with 95% confidence intervals were calculated. The seroprevalence of T. gondii was 77.7% in cases and 89.0% in healthy controls. T. gondii seropositivity showed a significant inverse association with AD in both univariate analysis (OR: 0.43, 95% CI: 0.18-0.98; P = 0.04) and multivariate analysis (OR: 0.35, 95% CI: 0.14-0.92; P = 0.03). Additionally, T. gondii seropositivity was significantly associated with lower odds of greater AD severity in multivariate analysis (OR: 0.44, 95% CI: 0.20-0.97; P = 0.04). Our findings suggest an inverse association between T. gondii seropositivity and AD. Moreover, seropositivity was associated with lower odds of more severe disease. Further research is warranted to clarify the biological basis and clinical significance of this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.